| metastatic/advanced UC (mUC) - 1st Line (L1) | metastatic/advanced UC (mUC) - 2nd Line (L2) | metastatic/advanced UC (mUC) - maintenance (M) | muscular invasive bladder cancer (MIBC) | |||||
| mUC - L1 - all population | mUC - L1 - PDL1 positive | mUC - L2 - all population | mUC - L2 - PDL1 positive | mUC - M - all population | mUC - M - PDL1 positive | MIBC - NA - all population | MIBC - NA - PDL1 positive | |
| anti-PD-(L)1 | ||||||||
| atezolizumab based treatment | ||||||||
| atezolizumab alone | IMvigor-130 ... | IMvigor-211 ... | IMvigor-211 ... IMvigor-211 ... | IMvigor-010 | ||||
| atezolizumab plus SoC | IMvigor-130 ... | |||||||
| avelumab based treatment | ||||||||
| avelumab alone | JAVELIN Bladder 100 ... | JAVELIN Bladder 100 ... | ||||||
| durvalumab based treatment | ||||||||
| durvalumab alone | DANUBE ... | DANUBE ... | ||||||
| nivolumab based treatment | ||||||||
| nivolumab alone | CheckMate 274 ... | CheckMate 274 ... | ||||||
| pembrolizumab based treatment | ||||||||
| pembrolizumab alone | KEYNOTE-361 ... | KEYNOTE-045 ... | KEYNOTE-045 ... | |||||
| pembrolizumab plus SoC | KEYNOTE-361 ... | |||||||
Study type:
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
